Pfizer (PFE) Commences Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate, PF-06482077

December 14, 2018 8:01 AM
Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles